The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-10 and is reviewed periodically as new material appears.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
=== Neurological pathways === Several brain pathways have been studied, and they seem to contribute to catatonia when they are not functioning properly. However, these studies were unable to determine if the abnormalities they observed were the cause of catatonia or if the catatonia caused the abnormalities. Furthermore, it has been hypothesized that pathways connecting the basal ganglia with the cortex and thalamus are involved in the development of catatonia.
=== Republic of Egypt (from 1953) === King Hussein of Jordan, 1955 Marshal Josip Broz Tito, President of the Federal People's Republic of Yugoslavia, 1956 Prof. Amintore Fanfani, Prime Minister and ad-interim Minister of Foreign Affairs of the Republic of Italy, 1959 Yuri Gagarin, Soviet cosmonaut, 1961 Taha Hussein, Egyptian writer, 1965 Umm kulthum, Egyptian singer and actress, 1965 Mohammed Abdel Wahab, Egyptian singer and composer, 1965 President Jimmy Carter, President of the United States, 1979 Emperor Akihito of Japan Emperor Amha Selassie of Ethiopia Mohammed Burhanuddin, 52nd Da'i al-Mutlaq of the Dawoodi Bohra, 1978 King Bhumibol Adulyadej of Thailand Mohamed ElBaradei, former director general of the International Atomic Energy Agency (IAEA) Queen Elizabeth II, 1975 Birendra Bir Bikram shah Dev, King of Nepal, 1974 Mohammad Reza Pahlavi, Shah of Iran, 1975 Hassaballah El Kafrawy, Egyptian former Minister of Housing Pengiran Anak Haji Mohamed Yusof, prince consort and cheteria of Brunei, 1984 Naguib Mahfouz, Egyptian writer, 1988 King Fahd bin Abdulaziz Al Saud of Saudi Arabia, 1989 Pierre Gemayel, founder of the Lebanese Phalange Emperor Haile Selassie of Ethiopia King Hamad bin Isa Al Khalifa of Bahrain, 2016 King Idris of Libya (Grand Cordon) Ekmeleddin İhsanoğlu, Turkish academic, diplomat and former Secretary-General of the Organisation of Islamic Cooperation (OIC) Émile Lahoud, President of Lebanon, 2000 Makarios III, former president of Cyprus Nelson Mandela, President of South Africa Adly Mansour, former Chief Justice of the Supreme Constitutional Court and former acting President of Egypt King Mohammed VI of Morocco Muhammad Naguib, First President of Egypt Nursultan Nazarbayev, President of Kazakhstan Antonín Novotný, President of Czechoslovakia Sultan Qaboos bin Said al Said of Oman, 1976 Ziaur Rahman, President of Bangladesh Heinrich Rau, East German politician (Grand Cordon), 1961 King Saud bin Abdulaziz Al Saud of Saudi Arabia, 1954 King Norodom Sihanouk of Cambodia William E. Simon, U.S. Secretary of the Treasury Suharto, President of Indonesia Field Marshal Mohamed Hussein Tantawi, former chairman of the Supreme Council of the Armed Forces of Egypt, 2012 Walter Ulbricht, President of East Germany, 1965 George Vasiliou, former president of Cyprus Sir Magdi Habib Yacoub, Egyptian professor of Cardiothoracic Surgery Professor Ahmed Zewail, Egyptian scientist Katerina Sakellaropoulou, President of Greece, 2020 Salva Kiir Mayardit, President of South Sudan, 2020 Haitham bin Tariq, Sultan of Oman, 2023 Narendra Modi, Prime Minister of India, 2023 Mufaddal Saifuddin, 53rd Da'i al-Mutlaq of the Dawoodi Bohras, 2023 Mishal Al-Ahmad Al-Jaber Al-Sabah, Emir of Kuwait, 2024 King Frederik X, King of Denmark, 2024 King Felipe VI, King of Spain, 2025 Donald Trump, President of the United States, 2025
== Histology == The epididymis is covered by a two-layered pseudostratified epithelium. The epithelium is separated by a basement membrane from the connective tissue wall, which has smooth muscle cells. The major cell types in the epithelium are:
=== Isomers of controlled psychedelics === In addition to explicitly controlled psychedelics, isomers of these compounds, for instance positional isomers, are controlled substances similarly under a new rule that became effective in 2008. Some examples of compounds affected by this rule, as explicitly defined by the DEA, include the following:
=== Biotic Theory === Most contemporary research into the origin of homochirality focuses on identifying abiotic mechanisms for chiral symmetry-breaking, amplification, and propagation/transmission that could have occurred during prebiotic synthesis of biomolecule precursors or during primitive replication/polymerization. Some early theories of biological homochirality in the 1950s suggested that homochiral biopolymers of both enantiomeric forms (e.g., both D-RNA and L-RNA) could have been present in the prebiotic Earth, and that polymers of the canonical enantiomeric forms were selected for due to improved chemical function. As an extension of this idea, it was also proposed that lifeforms containing both enantiomeric forms of molecular machinery could have arisen independently, and that evolution by natural selection eventually led to the complete dominance of one enantiomeric lifeform. This purely biotic theory is difficult to assess experimentally, and is not widely accepted or discussed in the scientific community.
Sources: en.wikipedia.org
=== United States and Canada === Methadone is a Schedule I controlled substance in Canada and Schedule II in the United States, with an ACSCN of 9250 and a 2014 annual aggregate manufacturing quota of 31,875 kilos for sale. Methadone intermediate is also controlled, under ACSCN 9226 also under Schedule II, with a quota of 38,875 kilos. In most countries of the world, methadone is similarly restricted. The salts of methadone in use are the hydrobromide (free base conversion ratio 0.793), hydrochloride (0.894), and HCl monohydrate (0.850). Methadone is also regulated internationally as a Schedule I controlled substance under the United Nations Single Convention on Narcotic Drugs of 1961.
NASA's aim for food on the ISS is to make the experience as close as possible to that of Earth, and they aim to provide more acceptable and palatable foods. Modern astronauts have a greater variety of main courses to choose from and many astronauts request personalized menus from lists of available foods including items like fruit salad and spaghetti. Fresh fruits and vegetables that can be safely stored at room temperature are eaten on space flights. Astronauts sometimes request beef jerky for flights, as it has an extended shelf life and a strong flavor. Food on the ISS is similar to the Shuttle, in that it is individually packaged to allow for exchanges and prevent issues in the microgravity environment. Due to the limited water supply, an emphasis has been placed on thermostabilized foods rather than rehydration methods. Since 2002, the small LADA Greenhouse system (the leaf chamber is just 16 x 20 x 26 cm/6 x 8 x 10 inches) has been used on board the International Space Station to study how plants grow in microgravity and to grow edible vegetables for the astronauts. LADA includes a control module and was sent to the station already equipped with the root media for the plants to be grown and eaten in space.
=== Attacks by Israel === On 25 April, the Lebanese Health Ministry reported that six people, four in Yohmor Al-Shaqeef, Nabatieh and two in Safad al-Battikh, Bint Jbeil, were killed by Israeli attacks under the orders of Israeli Prime Minister Benjamin Netanyahu to "forcefully attack Hezbollah targets" after the IDF accused the group of breaching the ceasefire agreement. On 26 April, the Lebanese Health Ministry stated that 14 people, including two women and two children, were killed and 37 others were injured by Israeli attacks in southern Lebanon. On 28 April, Israeli forces launched a double tap strike in Majdal Zoun, killing 9 people, including three emergency workers. The Israeli military stated that the strike targeted a Hezbollah commander operated in an Israeli-occupied area in southern Lebanon, despite providing no evidence. On 30 April, the National News Agency reported that several Israeli attacks targeted places in southern Lebanon, killing at least 28 people. President Joseph Aoun condemned Israel's "continuing violations", stating that "despite the ceasefire, as do demolitions of homes and places of worship, while the number of killed and wounded rises day after day". On 1 May, the Health Ministry of Lebanon reported that 13 people, including four women and a child, were killed by Israeli attacks in Habboush, Zrariyeh and Ain Baal. On 15 May, an Israeli airstrike targeted the town of Harouf, southern Lebanon, killing at least six people, including three paramedics.
Morgan State University (Morgan State or MSU) is a public historically black research university in Baltimore, Maryland, United States. It is the third largest among all Historically Black Colleges or Universities (HBCUs). In 1890, the university, then known as the Centenary Biblical Institute, changed its name to honor Lyttleton Morgan, the first chairman of its board of trustees and a donor. It became a university in 1975. Although a public institution, Morgan State is not a part of the University System of Maryland. It is a member of the Thurgood Marshall College Fund. It is accredited by the Middle States Commission on Higher Education. and classified among "R2: Doctoral Universities – High research activity".
Sources: en.wikipedia.org
Methods commonly used to study protein structure and function include immunohistochemistry, site-directed mutagenesis, X-ray crystallography, nuclear magnetic resonance and mass spectrometry. The activities and structures of proteins may be examined in vitro, in vivo, and in silico. In vitro studies of purified proteins in controlled environments are useful for learning how a protein carries out its function: for example, enzyme kinetics studies explore the chemical mechanism of an enzyme's catalytic activity and its relative affinity for various possible substrate molecules. By contrast, in vivo experiments can provide information about the physiological role of a protein in the context of a cell or even a whole organism, and can often provide more information about protein behavior in different contexts. In silico studies use computational methods to study proteins.
Bethlem myopathy may be diagnosed based on clinical examinations and laboratory tests may be recommended. Genetic testing for known pathological variants is preferred. In the case of a VUS, testing of dermal fibroblast culture is used for an accurate diagnosis. Bethlem myopathy 1 is a rare disease, affecting about 1 in 200,000 people. Bethlem myopathy 2 is an ultra-rare disease, affecting less than 1 in 1,000,000 people. The condition was described by J. Bethlem and G. K. van Wijngaarden in 1976.
The English word for tanning is from the medieval Latin verb tannāre, from the noun tannum (oak bark). This term may be derived from a Celtic word related to the Proto-Indo-European *dʰonu meaning 'fir tree'. (The same root is the source for Old High German tanna meaning 'fir', related to modern German Tannenbaum). Hide clothing, footwear, and shelters have been used since the Paleolithic, with evidence of leather working dated to approximately 400,000 years ago; leather working tools from this period being found at Hoxne, England dating to about 400,000 years ago. Extant vegetable oil tanned leather footwear, from the neolithic (c. 5,500-year-old), has been found in Areni-1 cave, of Vayots Dzor province of Armenia and on the remains of the Ötzi corpse, found on the Austria-Italy border. Ancient civilizations used leather for waterskins, bags, harnesses and tack, boats, armour, quivers, scabbards, boots, and sandals. Tanning was being carried out by the inhabitants of Mehrgarh in Pakistan between 7000 and 3300 BCE. Around 2500 BCE, the Sumerians began using leather, affixed by copper studs, on chariot wheels. The process of tanning was also used for boats and fishing vessels: ropes, nets, and sails were tanned using tree bark. Formerly, tanning was considered a noxious or "odoriferous trade" and relegated to the outskirts of town, among the poor. Tanning by ancient methods is so foul-smelling that tanneries are still isolated from those towns today where the old methods are used. Skins typically arrived at the tannery dried stiff and dirty with soil and gore.
=== U.S. production ceases and resumes === The United States stopped producing bulk 238Pu with the closure of the Savannah River Site reactors in 1988. Since 1993, all of the 238Pu used in American spacecraft has been purchased from Russia. From 1992 to 1994, 10 kilograms were purchased by the US Department of Energy from Russia's Mayak Production Association. Via agreement with Minatom, the US must use plutonium for uncrewed NASA missions, and Russia must use the currency for environmental and social investment in the Chelyabinsk region, affected by long-term radioactive contamination such as the Kyshtym disaster. In total, 16.5 kilograms (36 lb) have been purchased, but Russia is no longer producing 238Pu, and their own supply is reportedly running low. In February 2013, a small amount of 238Pu was successfully produced by Oak Ridge's High Flux Isotope Reactor, and on December 22, 2015, they reported the production of 50 grams (1.8 ounces) of 238Pu. In March 2017, Ontario Power Generation (OPG) and its venture arm, Canadian Nuclear Partners, announced plans to produce 238Pu as a second source for NASA. Rods containing neptunium-237 will be fabricated by Pacific Northwest National Laboratory (PNNL) in Washington State and shipped to OPG's Darlington Nuclear Generating Station in Clarington, Ontario, Canada where they will be irradiated with neutrons inside the reactor's core to produce 238Pu.
The study of mechanical or "formal" reasoning began with philosophers and mathematicians in antiquity. The study of logic led directly to Alan Turing's theory of computation, which suggested that a machine, by shuffling symbols as simple as "0" and "1", could simulate any conceivable form of mathematical reasoning. This, along with concurrent discoveries in cybernetics, information theory and neurobiology, led researchers to consider the possibility of building an "electronic brain". They developed several areas of research that would become part of AI, such as McCulloch and Pitts design for "artificial neurons" in 1943, and Turing's influential 1950 paper 'Computing Machinery and Intelligence', which introduced the Turing test and showed that "machine intelligence" was plausible. The field of AI research was founded at a workshop at Dartmouth College in 1956. The first AI program, Logic Theorist, was presented at the workshop, created by future Turing Award winner Allen Newell and future Nobel Laureate Herbert A. Simon, in collaboration with J. C. Shaw. Many of the workshop attendees became the leaders of AI research in the 1960s. They and their students produced programs that the press described as "astonishing": computers were learning checkers strategies, solving word problems in algebra, proving logical theorems and speaking English. Artificial intelligence laboratories were set up at a number of British and U.S. universities in the latter 1950s and early 1960s.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.